Author

J. R. Cochran

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Bioengineering· 2 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Assay:proteomics· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

C. L. Mackall· 2 shared L. Labanieh· 2 shared P. Xu· 2 shared A. Banuelos· 1 shared A. Chang· 1 shared A. Delaidelli· 1 shared A. E. Powell· 1 shared A. Fernandez· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

C. L. Mackall

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Engineered CD47 protects T cells for enhanced antitumor immunity

S. A. Yamada-Hunter, J. Theruvath, B. J. McIntosh, K. A. Freitas, M. T. Radosevich, A. Leruste, S. Dhingra, N. Martinez-Velez, P. Xu, A. Delaidelli, M. H. Desai, Z. Good, L. Labanieh, C. W. Mount, Y. Chen, , C. L. Mackall

This paper engineers a CD47 variant to protect T cells from macrophage clearance, enhancing antitumor efficacy by combining T cell and macrophage activation.

bioRxiv · Jun 20, 2023 · PreprintBioengineering

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8

A. Roy, L. Shi, A. Chang, X. Dong, A. Fernandez, J. C. Kraft, J. Li, V. Q. Le, R. V. Winegar, G. M. Cherf, D. Slocum, P. D. Poulson, G. E. casper, M. L. Vallecillo-Zuniga, J. C. Valdoz, , D. Baker

This paper designs highly selective miniprotein inhibitors for integrins αvβ6 and αvβ8 with picomolar affinity and therapeutic potential in a mouse fibrosis model.

bioRxiv · Jun 12, 2023 · PreprintBiochemistry

Mutational screens highlight glycosylation as a modulator of CSF3R activity

M. J. Hollander, S. A. Malaker, I. Perez, J. E. Maxson, J. R. Cochran, C. R. Bertozzi

The paper identifies glycosylation sites as critical for CSF3R activity and shows that mutations at these sites can lead to ligand-independent cell growth in chronic neutrophilic leukemia.

bioRxiv · Aug 1, 2022 · PreprintBiochemistry

Delivery of CAR-T Cells in a Transient Injectable Stimulatory Hydrogel Niche Improves Treatment of Solid Tumors

A. K. Grosskopf, L. Labanieh, D. D. Klysz, G. Roth, P. Xu, O. Adebowale, E. C. G. C. Gale, C. K. Jons, J. H. Klich, J. Yan, C. L. Maikawa, S. Correa, B. S. Ou, A. I. d'Aquino, J. R. Cochran, , E. Appel

This paper develops an injectable hydrogel to co-deliver CAR-T cells and cytokines, enhancing solid tumor treatment in mice by creating a transient inflammatory niche.

bioRxiv · Dec 20, 2021Bioengineering

Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library

B. N. Bell, A. E. Powell, C. Rodriguez, J. R. Cochran, P. S. Kim

The paper isolates and characterizes three novel neutralizing antibodies against SARS-CoV-2 RBD from a naive human antibody library, showing they neutralize the virus in vitro.

bioRxiv · Jan 7, 2021Immunology

Structure and Functional Binding Epitope of V-domain Ig Suppressor of T-cell Activation (VISTA)

N. Mehta, S. Maddineni, I. I. Mathews, A. P. Sperberg, P.-S. Huang, J. R. Cochran

This study determines the crystal structure of human VISTA and identifies its binding epitope for an anti-VISTA antibody and VSIG3.

bioRxiv · Apr 3, 2019Cancer Biology